Clinical Trials
18 trialsNCT04481204 2026-05-04
New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03161522 2026-04-15
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT03776487 2026-04-15
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00707473 2026-03-05
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT04539808 2026-01-14
NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT05699603 2025-09-24
Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients
University of Arizona
Phase 2 Active not recruiting
NCT06780787 2025-06-26
FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery
City of Hope Medical Center
Phase 2 Recruiting
NCT03073785 2025-05-25
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Active not recruiting
NCT03736720 2025-01-30
Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01307956 2023-10-26
Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer
University of Nebraska
Phase 2 Terminated
NCT01959672 2023-10-10
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT02427841 2023-09-06
Nab-paclitaxel and Gemcitabine Hydrochloride Followed by Radiation Therapy Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
OHSU Knight Cancer Institute
Phase 2 Completed
NCT03690921 2023-06-29
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05733000 2023-03-10
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Northwestern University
Phase 2 Recruiting
NCT03617913 2023-01-06
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Mayo Clinic
Phase 2 Completed
NCT02508077 2018-08-16
FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer
City of Hope Medical Center
Phase 2 Terminated